In an interview conducted at the Association for Research in Vision and Ophthalmology Annual Meeting, May 5-9, 2023, Jordana Fein, MD, MS, Retina Group of Washington Fairfax, Virginia, discussed results of a post hoc analysis of the CANDELA study. Dr Fein described the primary and secondary endpoints and the potential clinical impact of the findings.
Wet age-related macular degeneration (AMD) is a chronic, progressive eye disease marked by abnormal blood vessel growth beneath the retina. These fragile vessels can leak fluid or blood…
Andrew Chang, MBBS, PhD, consultant ophthalmologist and head of Ophthalmology, Sydney Eye Hospital, Australia, shares real-world experience using 8-mg intravitreal aflibercept for neovascular age-related macular degeneration and reports…
Diabetic macular edema (DME) is a leading cause of vision loss in people with diabetes. It occurs when long-term high blood sugar damages retinal blood vessels, causing them…
Charles Wykoff, MD, PhD, joins Diane Bovenkamp, PhD, for a Macular Chat hosted by BrightFocus Foundation and ASRS to discuss the current landscape and future of wet age-related…
Kelvin Teo, MBBS, PhD, senior consultant, Advanced Eye Clinic & Surgery, adjunct associate professor, Duke NUS Eye ACP, Singapore, presents real-world data showing that a single 8-mg dose…
Age-related macular degeneration (AMD) is the leading cause of vision loss in older Americans, affecting the central part of the retina called the macula. Alla Goldberg, MD, a…
Jean-Francois Korobelnik, MD, professor of ophthalmology, University Hospital of Bordeaux, explained findings of an analysis of the Phase 3 PULSAR trial designed to assess disease activity control. Dr…
Deepak Sambhara, MD, Eye Clinic of Wisconsin, discusses results from a post hoc analysis of the Phase 2/3 PHOTON trial investigating the impact of central retinal thickness on…
Starting diabetic macular edema treatment with bevacizumab and switching to aflibercept if needed offers nearly identical vision outcomes to aflibercept monotherapy, but at a far lower cost. A…
Anti-VEGF injections are a common treatment for wet age-related macular degeneration (AMD), aimed at preserving or even improving vision by stopping abnormal blood vessel growth under the macula.…
